Company intelligence / Profile preview

Kashcool

Bridgewater, New Jersey, USAsalonatcom.com ↗

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Kashiv has multiple programs in development including biosimilars such as ADL018/AVT23 (omalizumab), which is in global Phase III trials. They have received marketing authorization for pegfilgrastim injection from Health Canada and reported successful Phase 1 results for an abatacept biosimilar candidate. Their approach focuses on expanding access to affordable biologic and complex medicines.

Therapeutic areas: PulmonologyImmunologyHematology
Modalities: Monoclonal antibodyPeptidesSmall molecule
Industry: Biotech

Partnerships

Alvotech – exclusive licensing agreement for commercialization of omalizumab biosimilar across EU27 + UK/Australia/Canada/NZ

Beyond the preview

Go deeper on Kashcool.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kashcool.

Explore the full profile